Humana (HUM) – Analysts’ Recent Ratings Updates
A number of firms have modified their ratings and price targets on shares of Humana (NYSE: HUM) recently:
- Humana had its “outperform” rating reaffirmed by analysts at Wells Fargo & Co..
- Humana was downgraded by analysts at Credit Suisse from an “outperform” rating to a “neutral” rating. They now have a $74.00 price target on the stock, down previously from $94.00. They wrote, “HUM is a leading managed care provider leveraged to the Medicare Advantage (MA) market in which we see significant long-term growth opportunities, driven by increases in the 65-plus population and greater MA penetration. The company is best positioned to capture this opportunity, given its focus, expertise, and market share in MA, while its conservative balance sheet and strong financial position allows for flexibility in capital deployment.”
- Humana was upgraded by analysts at Leerink Swann from a “market perform” rating to an “outperform” rating.
- Humana had its “outperform” rating reaffirmed by analysts at Oppenheimer.
- Humana had its “positive” rating reaffirmed by analysts at Susquehanna. They now have a $85.00 price target on the stock.
Shares of Humana traded up 0.78% during mid-day trading on Friday, hitting $72.23. Humana has a one year low of $59.92 and a one year high of $96.46. The company has a market cap of $11.680 billion and a P/E ratio of 9.51.
Humana Inc. (Humana) is a health care company. Humana operates in three segments: Retail, Employer Group, and Health and Well-Being Services.